• Privacy Policy
LSD News
  • Home
  • Business
  • Crypto News
  • Finance
  • Health
  • Politics
  • Sports
  • Stock
  • Tech
  • Travel
No Result
View All Result
  • Home
  • Business
  • Crypto News
  • Finance
  • Health
  • Politics
  • Sports
  • Stock
  • Tech
  • Travel
No Result
View All Result
LSD News
No Result
View All Result
Home Health

FDA approves first RSV vaccine for pregnancy to protect newborns

by
August 22, 2023
in Health
0
FDA approves first RSV vaccine for pregnancy to protect newborns
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


Expectant parents could soon have another new option this fall to protect their newborns from RSV, or respiratory syncytial virus, the most common cause of hospitalization in American infants, after the Food and Drug Administration announced Monday that it has widened its approval for Pfizer’s Abrysvo vaccine to include expectant mothers. 

Pregnant women would receive immunity from the shot during pregnancy then pass that along to their baby before birth, offering protection in the infant’s earliest months of life. 

“This approval provides an option for healthcare providers and pregnant individuals to protect infants from this potentially life-threatening disease,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, in a release announcing the approval.

Pfizer’s new approval follows a favorable vote from the FDA’s outside vaccine advisers in May, after results finding the shot had 69.4% efficacy in lowering the risk of severe lower respiratory tract illness in babies through six months after birth.  

If the Centers for Disease Control and Prevention concurs, the shot would be added to a list of “maternal vaccines” recommended before birth, buoying the chances of newborns making it safely through some of their most vulnerable months of life. 

“Today, a long-sought-after goal to deliver a maternal vaccine that will help protect infants six months of age or younger – when they are at greatest risk of possible serious consequences from RSV – has been achieved,” Annaliesa Anderson, Pfizer’s chief scientific officer of vaccine research and development, said in a statement. 

While nearly all children will have survived at least one RSV infection by age 2, the virus can be especially dangerous to babies who contract their first bout of the disease in their youngest months.

The FDA had previously approved Pfizer’s Abrysvo vaccine only for use in older adults. Adults ages 60 and older are recommended to talk to their doctors about potentially getting the shot.

The CDC’s Advisory Committee on Immunization Practices will need to meet again to weigh updated recommendations for the shots during pregnancy. 

While doctors are not bound by law to follow the panel’s recommendations, they do play a key role deciding requirements for insurance coverage of the vaccines. 

A second option for protecting newborns

The latest approval follows another option that was recently greenlighted to protect babies from RSV: nirsevimab, an antibody injection which is now being marketed as Beyfortus by drugmakers Sanofi and AstraZeneca. 

After a meeting in early August, the CDC had signed off on new recommendations urging parents of babies born into their first RSV season this fall and winter to get them the Beyfortus shot.

But agency officials acknowledged the committee would need to meet again to vote on new recommendations if Abrysvo was also approved by the FDA, sorting out how it might affect their new guidance.

Both Abrysvo and Beyfortus appeared to be safe and effective in trials at curbing RSV hospitalizations in babies, a work group convened by the agency reported earlier this year. 

However, preliminary calculations presented  to the committee suggest it would not be cost effective to issue recommendations for giving both shots, which together were modeled to cost $700 for each child before insurance. 

Instead, the CDC may end up favoring recommendations to offer Abrysvo first. 

Beyfortus would effectively be a backup, under their draft guidance, largely offered only to babies born to parents who did not get Abyrsvo during pregnancy or who are at higher risk of severe disease.

Questions about very rare preterm births

Further complicating the new recommendations are a handful of very rare preterm births seen in babies of moms who received Abrysvo during pregnancy. 

While the number in Pfizer’s trial was too small to be statistically significant, it came after a larger uptick in preterm births was big enough to force GSK to halt a separate RSV vaccine trial in pregnant women earlier this year. 

“We have had long discussions about whether or not there could, or is not, a biologic plausibility to this,” the CDC’s Katherine Fleming Dutra told the ACIP at a meeting in June.

This puzzled some on the FDA’s vaccines panel earlier this year as well. While they voted unanimously in favor of its effectiveness, the panel split 10 to 4 voting in favor of whether there was enough data on Abrysvo’s safety to back its approval. 

“I’m troubled, as everybody is, by the prematurity issue. And I’m not sure that running it through another maybe season is going to give us an answer. And I think we’ve heard that observational studies, as we go forward, will fairly quickly give us an answer if there is a problem there,” Dr. Arnold Monto, one of the FDA committee’s members, said at the meeting.

The FDA said Monday it would require Pfizer “to conduct postmarketing studies” to assess the risk of preterm birth, and will include a warning about the “numerical imbalance.”

“The available data are insufficient to establish or exclude a causal relationship between preterm birth and Abrysvo,” the agency said.

Trending News

Alexander Tin

CBS News reporter covering public health and the pandemic.

Related

Tags: ApprovesFDAnewbornspregnancyProtectRespiratory Syncytial VirusRSVvaccine
Previous Post

Stocks making the biggest moves midday: Palo Alto Networks, Nvidia, Tesla, Marvell and more

Next Post

Brother of Dikwella shooting victim arrested for aiding and abetting

Next Post
Brother of Dikwella shooting victim arrested for aiding and abetting

Brother of Dikwella shooting victim arrested for aiding and abetting

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stay Connected test

  • 131 Followers
  • 23.9k Followers
  • 99 Subscribers
ADVERTISEMENT
  • Trending
  • Comments
  • Latest
Hawaii officials work to address mental health challenges facing wildfire survivors

Hawaii officials work to address mental health challenges facing wildfire survivors

August 17, 2023
Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs

Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugs

August 10, 2023
Working-age Americans are struggling to pay for health care, even those with insurance, report finds

Working-age Americans are struggling to pay for health care, even those with insurance, report finds

October 28, 2023

Aron Szabo: The Hungarian voice of the American legal profession

September 27, 2023
Ethereum Price To Reclaim $1,300, What Are The Possibilities?

Ethereum Price To Reclaim $1,300, What Are The Possibilities?

0
Tech layoffs in Southeast Asia mount as unprofitable startups seek to extend their runways

Tech layoffs in Southeast Asia mount as unprofitable startups seek to extend their runways

0
Stock market update: Stocks that hit 52-week lows on NSE in today’s trade

Stock market update: Stocks that hit 52-week lows on NSE in today’s trade

0
Wealthy Chinese keep on spending while others cut back, survey finds

Wealthy Chinese keep on spending while others cut back, survey finds

0
This sector gave positive returns in December last 3 years, will history repeat?

This sector gave positive returns in December last 3 years, will history repeat?

December 2, 2023
How $100 billion mining giant Rio Tinto is poised to benefit from the EV boom

How $100 billion mining giant Rio Tinto is poised to benefit from the EV boom

December 2, 2023
Hashdex Submits Revised Bitcoin Spot ETF Filing To The SEC, Here’s What Changed | Bitcoinist.com

Hashdex Submits Revised Bitcoin Spot ETF Filing To The SEC, Here’s What Changed | Bitcoinist.com

December 2, 2023
Case for gold fever: NewEdge Wealth sees record rush intensifying

Case for gold fever: NewEdge Wealth sees record rush intensifying

December 2, 2023

Recent News

This sector gave positive returns in December last 3 years, will history repeat?

This sector gave positive returns in December last 3 years, will history repeat?

December 2, 2023
How $100 billion mining giant Rio Tinto is poised to benefit from the EV boom

How $100 billion mining giant Rio Tinto is poised to benefit from the EV boom

December 2, 2023
Hashdex Submits Revised Bitcoin Spot ETF Filing To The SEC, Here’s What Changed | Bitcoinist.com

Hashdex Submits Revised Bitcoin Spot ETF Filing To The SEC, Here’s What Changed | Bitcoinist.com

December 2, 2023
Case for gold fever: NewEdge Wealth sees record rush intensifying

Case for gold fever: NewEdge Wealth sees record rush intensifying

December 2, 2023

We bring the latest news from all over the world and get all time updated you

Follow Us

Browse by Category

  • Arts & Entertainment, Music
  • Arts & Entertainment, Photography
  • Business
  • Business, Careers
  • Business, Customer Service
  • Business, Home Based Business
  • Business, Marketing
  • Business, Sales
  • Communications, Mobile Phones
  • Computers, Data Recovery
  • Computers, Games
  • Computers, Hardware
  • Crypto News
  • Disease & Illness, Breast Cancer
  • Fashion, Jewelry
  • Finance
  • Finance, Credit
  • Finance, Currency Trading
  • Finance, Investing
  • Finance, Real Estate
  • Finance, Taxes
  • Food & Beverage, Coffee
  • Food & Beverage, Gourmet
  • Food & Beverage, Wine
  • Health
  • Health & Fitness, Acne
  • Health & Fitness, Cardio
  • Health & Fitness, Diabetes
  • Health & Fitness, Exercise
  • Health & Fitness, Medicine
  • Health & Fitness, Weight Loss
  • Home & Family, Crafts
  • Home & Family, Gardening
  • Home & Family, Hobbies
  • Home & Family, Holidays
  • Home & Family, Home Improvement
  • Home & Family, Home Security
  • Home & Family, Landscaping
  • Home & Family, Pets
  • Internet Business, Affiliate Programs
  • Internet Business, Audio-Video Streaming
  • Internet Business, Blogging
  • Internet Business, Ecommerce
  • Internet Business, Email Marketing
  • Internet Business, Podcasts
  • Internet Business, SEO
  • Internet Business, Site Promotion
  • Internet Business, Web Design
  • Politics
  • Politics, Commentary
  • Politics, Current Events
  • Product Reviews, Book Reviews
  • Product Reviews, Consumer Electronics
  • Product Reviews, Movie Reviews
  • Product Reviews, Music Reviews
  • Recreation & Sports, Biking
  • Recreation & Sports, Fishing
  • Recreation & Sports, Martial Arts
  • Reference & Education, College
  • Reference & Education, Homeschooling
  • Reference & Education, K-12 Education
  • Reference & Education, Sociology
  • Self Improvement, Coaching
  • Self Improvement, Creativity
  • Self Improvement, Happiness
  • Society, Divorce
  • Society, Sexuality
  • Society, Weddings
  • Sports
  • Stock
  • Tech
  • Travel
  • Travel & Leisure, Aviation
  • Travel & Leisure, Destinations
  • Travel & Leisure, Travel Tips
  • Travel & Leisure, Vacations
  • Uncategorized
  • Vehicles, Boats
  • Vehicles, Cars
  • Writing & Speaking, Writing

Recent News

This sector gave positive returns in December last 3 years, will history repeat?

This sector gave positive returns in December last 3 years, will history repeat?

December 2, 2023
How $100 billion mining giant Rio Tinto is poised to benefit from the EV boom

How $100 billion mining giant Rio Tinto is poised to benefit from the EV boom

December 2, 2023
  • Privacy Policy

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

No Result
View All Result
  • Privacy Policy

© 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

  • bitcoinBitcoin(BTC)$35,404.002.62%
  • ethereumEthereum(ETH)$1,834.511.58%
  • tetherTether(USDT)$1.000.05%
  • binancecoinBNB(BNB)$230.812.55%
  • rippleXRP(XRP)$0.610.69%
  • usd-coinUSDC(USDC)$1.00-0.05%
  • solanaSolana(SOL)$43.8211.48%
  • staked-etherLido Staked Ether(STETH)$1,833.391.69%
  • cardanoCardano(ADA)$0.3098437.47%
  • dogecoinDogecoin(DOGE)$0.0699594.44%
  • tronTRON(TRX)$0.1003142.05%
  • ToncoinToncoin(TON)$2.201.43%
  • VectoriumVectorium(VECT)$425.81-3.49%
  • chainlinkChainlink(LINK)$11.221.48%
  • matic-networkPolygon(MATIC)$0.676.54%
  • polkadotPolkadot(DOT)$4.748.08%
  • wrapped-bitcoinWrapped Bitcoin(WBTC)$35,382.002.69%
  • Wrapped stETHWrapped stETH(WSTETH)$1,864.880.36%
  • litecoinLitecoin(LTC)$70.122.70%
  • bitcoin-cashBitcoin Cash(BCH)$243.091.20%
  • shiba-inuShiba Inu(SHIB)$0.0000083.84%
  • avalanche-2Avalanche(AVAX)$12.017.66%
  • daiDai(DAI)$1.000.07%
  • leo-tokenLEO Token(LEO)$3.89-2.12%
  • uniswapUniswap(UNI)$4.6914.32%
  • stellarStellar(XLM)$0.120970-1.09%
  • true-usdTrueUSD(TUSD)$1.000.23%
  • ftx-tokenFTX(FTT)$23.71-3.46%
  • moneroMonero(XMR)$171.280.18%
  • Bitcoin Cash ABCBitcoin Cash ABC(BCHA)$151.06-6.64%
  • okbOKB(OKB)$45.561.24%
  • ethereum-classicEthereum Classic(ETC)$17.690.18%
  • BitTorrentBitTorrent(BTT)$0.003681-1.64%
  • cosmosCosmos Hub(ATOM)$7.932.86%
  • binance-usdBUSD(BUSD)$1.000.00%
  • hedera-hashgraphHedera(HBAR)$0.0551277.19%
  • filecoinFilecoin(FIL)$3.944.61%
  • internet-computerInternet Computer(ICP)$4.075.54%
  • AptosAptos(APT)$7.030.90%
  • crypto-com-chainCronos(CRO)$0.0630372.69%
  • lido-daoLido DAO(LDO)$1.852.02%
  • quant-networkQuant(QNT)$103.420.82%
  • nearNEAR Protocol(NEAR)$1.467.26%
  • vechainVeChain(VET)$0.0194284.35%
  • aaveAave(AAVE)$95.4516.20%
  • injective-protocolInjective(INJ)$15.5911.92%
  • ArbitrumArbitrum(ARB)$1.016.10%
  • MantleMantle(MNT)$0.4025286.42%
  • optimismOptimism(OP)$1.422.60%
  • Shiba SagaShiba Saga(SHIA)$0.151738-15.33%